CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics公司已獲得FDA批准，可啓動CER-1236用於急性髓細胞白血病的I期臨床試驗的調查新藥申請。
CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics, Inc.收到FDA批准其新藥申請，以啓動CER-1236用於急性髓系白血病的I期臨床試驗。
資訊熱榜
更新時間